The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2009Potential Efficacy of a Novel HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
Histone deacetylases (HDACs) are a family of enzymes that reduce gene expression and can regulate protein clearance. Inhibitors of HDACs have been reported to be efficacious in... -
Biomarkers, 2007Prospective Validation of Risk Markers for the Development of Parkinson’s Disease
Objective/Rationale:
The development of disease-course modifying or neuroprotective treatments is still an unmet therapeutical need in Parkinson’s disease. Treatment will likely work best if initiated... -
Research Grant, 2017Validation of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) for Parkinson's Disease
Study Rationale:
The US Food and Drug (FDA) requires acceptable outcome measures to approve a cognitive-enhancing medication for the treatment of mild cognitive impairment (MCI) in Parkinson's disease... -
MJFF Research Grant, 2011Multimodal MRI Markers for Parkinson's Disease
Objective/Rationale:
A measurement tool which accurately reflects not only motor deficits but also a host of cognitive dysfunctions seen frequently in Parkinson’s disease (PD) would improve diagnosis... -
Research Grant, 2021Comparing the Effectiveness of Two Imaging Methods for Monitoring the Progression of Parkinson’s Disease
Study Rationale:
Parkinson’s disease robs the brain of dopamine, a neurochemical needed for normal movement and cognition. A variety of imaging methods can be used to monitor the brain’s dopamine... -
Access to Data and Biospecimens, 2015BioFIND: Analysis of A-beta, Tau and P-tau in CSF Samples
Study Rationale: Mixed pathology is common in all neurodegenerative diseases including Parkinson’s disease (PD). Three cerebrospinal fluid (CSF) biomarkers, Ab1-42, t-tau and p-tau181, provide an...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.